Table 3.
Distribution of selected variables in patients stratified according to response to eltrombopag.
| Variable | Responders (n = 29) |
Non-Responders (n = 9) |
p |
|---|---|---|---|
| Age | 59.8 (48.0, 64.5) | 58.4 (53.8, 67.3) | 0.810 |
| Sex (female), n/N (%) | 15/29 (51.7) | 2/9 (22.2) | 0.148 |
| Diagnosis (DLBCL), n/N (%) | 27/29 (93.1) | 7/9 (77.8) | 0.233 |
| Cytopenia before CART infusion (%) | 8/29 (27.5) | 2/9 (22) | 0,573 |
| Disease in progression before CART (%) | 15/29 (51.7) | 5/9 (55.5) | 0,945 |
| Bridge therapy (%) | 6/29 (20.7) | 2/9 (22) | 0,338 |
| PLT count at ELT start (×109/L) | 12 (9, 15) | 15 (9, 23) | 0.633 |
| Time between PLT transfusion start and ELT start, days | 15 (6, 46) | 36 (22, 68) | 0.196 |
| DP before the end of the study, n/N (%) | 9/29 (31.0) | 3/9 (33.3) | 1.000 |
| Exitus before the end of the study, n/N (%) | 13/29 (44.8) | 7/9 (77.8) | 0.130 |
Results are median (IQR) except otherwise specified. Responders and non-responders were patients who either achieved or did not achieve platelet transfusion independence by the last follow-up visit. Comparisons were performed using the two-tailed Mann-Whitney U test and the two-tailed Fisher exact test for continuous and categorical variables, respectively. DP, disease progression; ELT, eltrombopag; IQR, interquartile range; PLT, platelets.